{"schema_version":"secwatch.filing_event.v1","accession":"0001110803-24-000049","form_type":"8-K","ticker":"ILMN","cik":"0001110803","company_name":"ILLUMINA, INC.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.697524+00:00","generated_at":"2026-05-30T05:47:42.008843+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Illumina Q3 Core revenue $1.08B (-2% YoY); raises FY24 non-GAAP EPS guide to $4.05-$4.15","bullets":["Core Illumina revenue $1.08B, down 2% YoY; GAAP diluted EPS $4.03, non-GAAP $1.14.","Lowered FY2024 Core revenue guidance to ~3% decline; Q4 revenue expected ~$1.07B.","Raised FY2024 non-GAAP operating margin guidance to 21%-21.5% and non-GAAP diluted EPS to $4.05-$4.15.","Free cash flow $284M in Q3, up from $94M YoY; cash & short-term investments $939M.","Introduced MiSeq i100 Series, FDA approval for TSO Comprehensive, GRAIL spin-off completed June 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001110803-24-000049","json":"https://secwatch.observer/filing/0001110803-24-000049.json","markdown":"https://secwatch.observer/filing/0001110803-24-000049.md","text":"https://secwatch.observer/filing/0001110803-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1110803/000111080324000049/0001110803-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1110803/000111080324000049/ilmn-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:47:42.008843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}